These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38376624)

  • 21. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
    Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
    PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer: cardiovascular mortality and androgen deprivation.
    Basaria S
    Nat Rev Urol; 2009 May; 6(5):252-3. PubMed ID: 19424172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.
    Carneiro A; Sasse AD; Wagner AA; Peixoto G; Kataguiri A; Neto AS; Bianco BA; Chang P; Pompeo AC; Tobias-Machado M
    World J Urol; 2015 Sep; 33(9):1281-9. PubMed ID: 25387877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contemporary role of androgen deprivation therapy for prostate cancer.
    Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
    Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
    Taylor LG; Canfield SE; Du XL
    Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
    Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.
    Lowentritt B; Fallick M; Pruett J; Jiang T; Li E; Brown B; Dufour R
    Urol Pract; 2024 Jan; 11(1):154-161. PubMed ID: 37914225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
    Kim J; Freeman K; Ayala A; Mullen M; Sun Z; Rhee JW
    Curr Oncol Rep; 2023 Sep; 25(9):965-977. PubMed ID: 37273124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
    MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
    Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk.
    Melloni C; Nelson A
    J Cardiovasc Transl Res; 2020 Jun; 13(3):451-462. PubMed ID: 31833002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
    Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgens and prostate cancer; pathogenesis and deprivation therapy.
    Grossmann M; Cheung AS; Zajac JD
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].
    Klemm J; von Deimling M; Fisch M; Kramer G; Tilki D; Steuber T; von Amsberg G; Hengstenberg C; Shariat SF
    Urologie; 2024 Mar; 63(3):262-268. PubMed ID: 37874334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections.
    Kakkat S; Pramanik P; Singh S; Singh AP; Sarkar C; Chakroborty D
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.
    Alwhaibi A; Alsanea S; Almadi B; Al-Sabhan J; Alosaimi FD
    Aging Male; 2022 Dec; 25(1):101-124. PubMed ID: 35343371
    [No Abstract]   [Full Text] [Related]  

  • 40. Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer.
    Gheorghe GS; Hodorogea AS; Ciobanu A; Nanea IT; Gheorghe ACD
    Curr Oncol; 2021 Aug; 28(5):3331-3346. PubMed ID: 34590590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.